- Seeing the Side Effects: Ocular Toxicity Associated with Systemic Therapeutics
-
Stars at Night Ballroom B1‚ Convention Center
Chair: Yu-Quan Wen, Abbvie Inc.
Co-Chair: Vladimir Bantseev, Genentech Inc.
Primary Endorser: Ocular Toxicology Specialty SectionThis session will provide a focused, multi-perspective discussion of ocular toxicity associated with systemically administered therapeutics, a topic of growing importance as oncology and immunology drug discovery continues to expand through genomics, transcriptomics, proteomics, and other target-identification strategies. As new modalities advance through development, unintended effects on visual function have emerged as an increasingly important safety concern, reinforcing the need to integrate toxicology, pathology, translational science, and human-relevant models to better define risk and support drug development decisions. First, a pathology-focused presentation will review common ocular lesions associated with systemically administered therapeutics, highlight background findings that may mimic treatment-related toxicity, and discuss how class- or target-related effects should inform postmortem ocular evaluation in systemic toxicology studies. Second, an ADC-focused presentation will address antibody-drug conjugate–associated ocular toxicity using an acute rodent model strategy designed to improve translatability and identify clinically relevant corneal findings earlier in development. Third, a translational presentation on crizotinib-associated visual disturbances will examine retinal functional changes and evidence suggesting a mechanism related to retinal signaling rather than ALK inhibition. Fourth, a translational presentation on iPSC-derived 2D and 3D outer blood–retina barrier models will describe human-relevant platforms for screening ocular toxicity risk, including mechanistic interrogation of pathways relevant to drug-induced retinal and RPE injury. Together, these talks will provide attendees with an integrated view of class-specific ocular liabilities, histopathologic interpretation, translational model systems, and emerging methods that may improve early detection, characterization, and assessment of ocular safety risks across therapeutic modalities.
Session and Activity Type
Enter Note
Go to previous page in this tab
Event
